We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GMED - GenoMed Inc. -- Ignore unavailable to you. Want to Upgrade?

To: donpat who wrote (298)6/22/2006 9:55:53 AM
From: jmhollen  Respond to of 347
They seem to have the goods, but they're bucking the snooty AMA establishment.

If they had/received the funding to do proper marketing and break out, it could be a good one.

John :-)


To: donpat who wrote (298)6/28/2006 7:45:37 PM
From: Tadsamillionaire  Read Replies (1) | Respond to of 347
GenoMed CEO Invited to Lecture at University of Chicago About Bird Flu
ST. LOUIS, June 21 /PRNewswire-FirstCall/ -- GenoMed (Pink Sheets: GMED), a Next Generation Disease Management company whose business is global public health(TM), today announced that its CEO was invited to speak at the Department of Medicine of the University of Chicago about diseases associated with the angiotensin I-converting enzyme (ACE), including avian influenza ('bird flu').

Dr. Skip Garcia, Chairman of the Medicine Department, invited GenoMed's CEO, David Moskowitz, MD, for a two day Visiting Lectureship that ended yesterday. Dr. Garcia is a world-famous lung specialist whose research group is looking for drugs to decrease the 'cytokine storm' created by the avian influenza virus.

GenoMed has filed patent applications claiming that ACE inhibitors and angiotensin II blockers can do exactly that. Furthermore, these drugs may be a near-universal viral antidote, because people who get sick from all viral diseases suffer from a 'cytokine storm.' GenoMed's viral antidote was included in the Project BioShield II Act of 2005, since it would be an ideal response to viral bioterrorism.

Said Dr. Moskowitz, GenoMed's CEO and Chief Medical Officer, 'GenoMed goes from the molecular mechanism of disease directly to practical treatments that are safe and useful at the population level. We're extremely gratified that a world-class research institution like the University of Chicago is thinking along exactly the same lines.